This is a type of anemia where the bone marrow, the part of the blood-forming tissue in bones, doesn't make enough new blood cells. This leads to a low red blood cell count, which can cause fatigue and weakness.
Every report comes from a Lived member, sent anonymously.
Have you had Stem Cell Transplant for Aplastic Anemia?
Aplastic anemia is a rare, serious disorder in which the bone marrow stops making enough new blood cells. Bone marrow is the spongy tissue inside bones where stem cells produce all three kinds of blood cells: red blood cells, which carry oxygen; white blood cells, which fight infection; and platelets, which help blood clot. In aplastic anemia those stem cells are damaged or lost, so all three counts fall together. The effects follow from which cells are missing. Too few red cells cause tiredness, weakness, pale skin, a fast heartbeat and breathlessness with exertion. Too few white cells make infections more frequent and more dangerous. Too few platelets lead to easy bruising, nosebleeds, bleeding gums, tiny red pinpoint spots on the skin and heavier periods. Despite the name, this is not the common anemia caused by low iron. It is a failure of the marrow itself, and it can appear suddenly or develop slowly, ranging from mild to life-threatening.
In most people, aplastic anemia is acquired rather than inherited, and the best-supported explanation is autoimmune: the immune system's own T cells attack the marrow's stem cells. Often no trigger is ever found, which doctors call idiopathic aplastic anemia. Some exposures are linked to it. Benzene, a solvent used in industry, can damage marrow directly. Certain medicines, a bout of hepatitis (liver inflammation), and some viral infections such as Epstein-Barr virus or HIV have been associated with it, as has pregnancy in rare cases. Radiation and chemotherapy for cancer also suppress the marrow, though that is an expected, usually temporary treatment effect. Most people with these exposures never develop aplastic anemia, so a link in one person's history is not proof of cause. A smaller group has an inherited bone marrow failure syndrome, such as Fanconi anemia or a telomere disorder (a genetic problem with the protective ends of chromosomes). These can first show up in adulthood without any family history, and they matter because they are treated differently.
Suspicion usually starts with a complete blood count showing low red cells, white cells and platelets at the same time (pancytopenia). A reticulocyte count, which measures the youngest red cells, is also low, showing that the marrow is not keeping up. The diagnosis is confirmed with a bone marrow aspirate and biopsy, in which a small sample is taken, usually from the back of the hip bone. In aplastic anemia the marrow looks sparse, with few blood-forming cells and much of the space filled with fat. The biopsy also helps rule out conditions that can look similar, especially hypoplastic myelodysplastic syndrome (a marrow disorder that can progress to leukemia) and leukemia itself. Severity is judged from the blood counts. It is classed as severe when at least two of these are present: neutrophils (the main infection-fighting white cells) below 500 per microliter, platelets below 20,000 per microliter, or reticulocytes below 20,000 per microliter. It is very severe when neutrophils fall below 200, a level at which serious infections become much more likely. Milder drops are called moderate aplastic anemia. Further testing looks for a cause and shapes treatment: a careful history of medicines, chemicals and infections; a test for cells from paroxysmal nocturnal hemoglobinuria (PNH), a related blood disorder that often coexists; and genetic testing when an inherited syndrome is possible. For anyone who might receive a transplant, tissue typing of the patient and their brothers and sisters is done early (HLA testing, which compares the immune markers a donor and recipient need to share), so a donor search does not delay treatment.
Treatment depends on severity, age, overall health and whether a matched donor is available. Moderate aplastic anemia may need no treatment beyond monitoring. Because the condition is rare and its care is complex, guidelines recommend involving a hematology team experienced with marrow failure. Supportive care runs alongside every other step. Red cell transfusions relieve anemia symptoms and platelet transfusions prevent or treat serious bleeding. When neutrophils are below 500, preventive antibiotics and antifungal medicines are often used, and any infection is treated quickly. Transfusions are lifesaving but have costs over time, including excess iron building up in the body and the immune system becoming harder to match with donor blood. Growth-factor injections that raise blood counts in other conditions, such as erythropoietin and filgrastim, do not correct aplastic anemia. The two treatments aimed at the disease itself work in different ways. A stem cell transplant (also called a bone marrow transplant) replaces the failing marrow with a donor's healthy blood-forming cells and can cure the condition. For children and adults up to about 40 who have a matched brother or sister, it is usually the preferred first treatment, and about 80 to 90 percent of young adults are alive and disease-free afterward. Its main risks are the donor cells failing to take hold and graft-versus-host disease, in which the donor's immune cells attack the recipient's body. These risks rise with age, so for people over 40, and for many without a matched sibling, immune-suppressing treatment usually comes first, with transplant kept as a later option. Immunosuppressive therapy calms the immune attack so the remaining stem cells can recover. It combines horse anti-thymocyte globulin (ATG, sold as Atgam), given by vein in the hospital, with cyclosporine, an oral immune-suppressing medicine, and usually eltrombopag (Promacta), a daily pill that stimulates blood-forming cells. Adding eltrombopag makes responses more likely and faster: in one randomized trial about half of people had responded by three months, compared with about a quarter on immunosuppression alone. Recovery is gradual, ATG can cause allergic and infusion reactions that are watched for closely, and eltrombopag requires regular liver tests. About a third of people do not respond to a first course, and some respond and later relapse. A second course of immunosuppression or a transplant is then considered, ideally within about six months if there is no response.
The course varies widely. Moderate aplastic anemia can stay stable for years with periodic blood counts and few symptoms. Severe aplastic anemia is life-threatening without treatment, but improvements in transplant, immunosuppression and supportive care mean that most people treated today, more than 80 to 90 percent in recent reports, become long-term survivors. Children generally respond well. The first months are often demanding. Blood counts are checked frequently, transfusions may be needed until the marrow recovers, and a hospital stay is usual for ATG or a transplant. While counts are low, daily life is shaped by infection precautions and by avoiding activities with a high risk of injury or bleeding. Fatigue and frequent transfusions weigh heavily on quality of life, so faster recovery is a real goal of treatment, not just a lab target. Counts often rise slowly and may not return fully to normal even when someone feels well and no longer needs transfusions. Follow-up continues for years. After immunosuppression, the condition can return, and roughly 10 to 15 percent of people later develop a related clonal marrow disorder such as myelodysplastic syndrome or acute myeloid leukemia. PNH can also emerge. Regular blood counts and, when needed, repeat marrow tests are how these changes are caught early. People who have had a transplant need their own long-term follow-up for graft-versus-host disease and other late effects.
Arrange an appointment if you have unexplained tiredness, infections that keep coming back, or bruising that appears with little or no injury, since a simple blood count can show whether the marrow is involved. If you have aplastic anemia, contact your care team right away for any fever, even if you otherwise feel well, because an infection can become serious quickly when white cells are low. Call promptly as well for new nosebleeds, bleeding gums, blood in the urine or stool, or a spreading rash of tiny red spots. Go to the emergency room for bleeding that is hard to stop.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Aplastic Anemia is like, what's helped you, or ask the community a question.